Celltrion gets first biosimilar approval

Published: 2012-07-25 07:00:00

Updated: 2012-07-25 07:00:00

Celltrion Inc., a local biopharmaceutical company, announced Monday that it has won the Korea Food and Drug Administration (KFDA)’s approval to produce Korea’s first antibody biosimilar ‘Remsima’ after seven years of clinical trials and development.

Biosimilar products are officially approved...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK